TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study

Autor: Yasuo Yamazaki, Kei Kimizuka, Hirofumi Yamada, Takashi Sakurai, Kazushige Futsuhara, Toru Kuroda, Masato Kojima, Sbccsg investigators, Kenichi Inoue, Shigenori Nagai, Satoshi Hata, Tsuyoshi Saito
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
medicine.medical_treatment
Phase II Studies
Triple Negative Breast Neoplasms
Docetaxel
chemistry.chemical_compound
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Clinical endpoint
Pharmacology (medical)
Triple-negative breast cancer
Titanium
Feasibility
Drug holiday
Middle Aged
Prognosis
Neoadjuvant Therapy
Survival Rate
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
Adult
medicine.medical_specialty
Paclitaxel
Bilirubin
Neoadjuvant chemotherapy
03 medical and health sciences
Internal medicine
TS-1
medicine
Humans
Adverse effect
Aged
Epirubicin
Pharmacology
Add-on therapy
Chemotherapy
business.industry
Silicates
Cancer
medicine.disease
Confidence interval
Adjuvant chemotherapy
030104 developmental biology
chemistry
Feasibility Studies
business
Follow-Up Studies
Zdroj: Investigational New Drugs
ISSN: 1573-0646
0167-6997
Popis: Summary Purpose We examined the feasibility, efficacy, and safety of TS-1 add-on therapy (TAT) in Japanese patients with triple-negative breast caner (TNBC). Methods TAT (TS-1, 80 mg/m2/day, BID, PO), consisting of the 21-day cycles of 14-day consecutive administration followed by 7-day drug holiday, was conducted for 365 days. The median follow-up was 75.2 months (range, 7.3–103.3 months). The primary endpoint was the feasibility of TAT. The secondary endpoints included relapse-free survival (RFS), overall survival (OS), and safety. Results 63 Japanese patients with TNBC (median age, 52.5 years; range, 23.7–68.6 years) were examined. Among them, 34 (54.0%) were postmenopausal, 54 (93.7%) had TNBC of common histological type, 51 (81.0%) had T1 to 3 tumors, 63 (100%) had undergone standardized surgery, and 44 (69.8%) and 19 (30.2%) had undergone neoadjuvant chemotherapy and adjuvant chemotherapy, respectively. The 365-day cumulative rate of TS-1 administration was 68.3% (95% confidence interval, 55.3–79.4), being comparable to 65.8% previously reported for gastric cancer. The 5-year RFS rates were 52.3% and 84.2% in the neoadjuvant and adjuvant chemotherapy groups, respectively, and the 5-year OS rates were 68.0% and 89.5%, respectively. The most common adverse events (AEs) were leucocyte count decreased (50.8%), total bilirubin decreased (44.4%), and pigmentation (42.9%). AEs were manageable clinically, and any grade 4 AEs did not develop. Conclusions The 365-day cumulative rate of TS-1 administration in TNBC patients was comparable to that in gastric cancer patients despite previous chemotherapy with anthracyclines and/or taxanes. TAT was feasible for TNBC patients after standard primary therapy.
Databáze: OpenAIRE
Externí odkaz: